Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Completed · Phase 3

Conditions studied: Influenza A Virus Infection

In brief

This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.

Key facts

Study ID
NCT02572817
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
138
Starts
2015-11-01
Expected to finish
2018-05-18
Last updated by the study team
2019-06-25

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.